Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F

Nature Structural and Molecular Biology

Volumn 19, Issue 8, 2012, Pages 754-759

  Bandaranayake, Rajintha M ^a   Ungureanu, Daniela ^b   Shan, Yibing ^c   Shaw, David E ^c,d   Silvennoinen, Olli ^b   Hubbard, Stevan R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c D E SHAW RESEARCH   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; SERINE; TYROSINE;

ANIMAL CELL; ARTICLE; BIOCHEMISTRY; CATALYSIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADENOSINE TRIPHOSPHATE; AMINO ACID SUBSTITUTION; BINDING SITES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; GENETIC COMPLEMENTATION TEST; HUMANS; JANUS KINASE 2; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MUTANT PROTEINS; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

EID: 84864668290     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.2348     Document Type: Article

References (47)

1. Ghoreschi, K., Laurence, A. & O'Shea, J.J. Janus kinases in immune cell signaling. Immunol. Rev. 228, 273-287 (2009).
2. Levy, D.E. & Darnell, J.E. Jr. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3, 651-662 (2002).
3. Lucet, I.S. et al. The structural basis of Janus kinase 2 inhibition by a potent and specifc pan-Janus kinase inhibitor. Blood 107, 176-183 (2006).
4. Boggon, T.J., Li, Y., Manley, P.W. & Eck, M.J. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106, 996-1002 (2005).
5. Williams, N.K. et al. Dissecting specifcity in the Janus kinases: the structures of JAK-specifc inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol. 387, 219-232 (2009).
6. Chrencik, J.E. et al. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J. Mol. Biol. 400, 413-433 (2010).
7. Vainchenker, W., Delhommeau, F., Constantinescu, S.N. & Bernard, O.A. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118, 1723-1735 (2011).
8. Haan, C., Behrmann, I. & Haan, S. Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J. Cell. Mol. Med. 14, 504-527 (2010).
9. Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790 (2005).
10. James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148 (2005).
11. Baxter, E.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061 (2005).
12. Levine, R.L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofbrosis. Cancer Cell 7, 387-397 (2005).
13. Lipson, D. Identifcation of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18, 382-384 (2012).
14. Russell, S.M. et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270, 797-800 (1995).
15. Saharinen, P. & Silvennoinen, O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277, 47954-47963 (2002).
16. Saharinen, P., Takaluoma, K. & Silvennoinen, O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20, 3387-3395 (2000).
17. Chen, M. et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol. Cell. Biol. 20, 947-956 (2000).
18. Lindauer, K., Loerting, T., Liedl, K.R. & Kroemer, R.T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng. 14, 27-37 (2001).
19. Ungureanu, D. et al. The pseudokinase domain of JAK2 is a dual-specifcity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18, 971-976 (2011).
20. Zheng, J. et al. 2.2 Å refned crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystallogr. D Biol. Crystallogr. 49, 362-365 (1993).
21. Hubbard, S.R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16, 5572-5581 (1997).
22. Shi, F., Telesco, S.E., Liu, Y., Radhakrishnan, R. & Lemmon, M.A. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. USA 107, 7692-7697 (2010).
23. Jura, N., Shan, Y., Cao, X., Shaw, D.E. & Kuriyan, J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc. Natl. Acad. Sci. USA 106, 21608-21613 (2009).
24. Dusa, A., Mouton, C., Pecquet, C., Herman, M. & Constantinescu, S.N. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specifc inhibitors. PLoS ONE 5, e11157 (2010).
25. Gnanasambandan, K., Magis, A. & Sayeski, P.P. The constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617. Biochemistry 49, 9972-9984 (2010).
26. Ni, Q., Shaffer, J. & Adams, J.A. Insights into nucleotide binding in protein kinase A using fuorescent adenosine derivatives. Protein Sci. 9, 1818-1827 (2000).
27. Argetsinger, L.S. et al. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol. Cell. Biol. 24, 4955-4967 (2004).
28. Ishida-Takahashi, R. et al. Phosphorylation of Jak2 on Ser(523) inhibits Jak2-dependent leptin receptor signaling. Mol. Cell. Biol. 26, 4063-4073 (2006).
29. Feener, E.P., Rosario, F., Dunn, S.L., Stancheva, Z. & Myers, M.G. Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol. Cell. Biol. 24, 4968-4978 (2004).
30. Mazurkiewicz-Munoz, A.M. et al. Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor. Mol. Cell. Biol. 26, 4052-4062 (2006).
31. Zhao, L. et al. A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation. J. Biol. Chem. 284, 26988-26998 (2009).
32. Livnah, O. et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283, 987-990 (1999).
33. Tefferi, A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 119, 2721-2730 (2012).
34. Kabsch, W. & Sander, C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22, 2577-2637 (1983).
35. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
36. Vagin, A.A. & Teplyakov, A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 30, 1022-1025 (1997).
37. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refnement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
38. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
39. Painter, J. & Merritt, E.A. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D Biol. Crystallogr. 62, 439-450 (2006).
40. Hornak, V. et al. Comparison of multiple Amber force felds and development of improved protein backbone parameters. Proteins 65, 712-725 (2006).
41. Lindorff-Larsen, K. et al. Improved side-chain torsion potentials for the Amber ff99SB protein force feld. Proteins 78, 1950-1958 (2010).
42. Jorgensen, W.L., Chandrasekhar, J., Madura, J.D., Impey, R.W. & Klein, M.L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926-935 (1983).
43. Shaw, D.E. et al. Millisecond-scale molecular dynamics simulations on Anton. in ACAM/IEEE Conference on Supercomputing (ACM, 2009).
44. Hoover, W.G. Canonical dynamics: Equilibrium phase-space distributions. Phys. Rev. A 31, 1695-1697 (1985).
45. Lippert, R.A. et al. A common, avoidable source of error in molecular dynamics integrators. J. Chem. Phys. 126, 046101 (2007).
46. Kräutler, V., Van Gunsteren, W.F. & Hunenberger, P.H. A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations. J. Comput. Chem. 22, 501-508 (2001).
47. Fennell, C.J. & Gezelter, J.D. Is the Ewald summation still necessary? Pairwise alternatives to the accepted standard for long-range electrostatics. J. Chem. Phys. 124, 234104 (2006).